Oliver Kuss1,2,3 · Michael Roden3,4,5 · Sabrina Schlesinger1,3 · Annika Hoyer6
Received: 27 May 2024 / Accepted: 23 November 2024 / Published online: 12 December 2024 © The Author(s) 2024
Abstract
Aims Two prerequisites must be met for the precision treatment approach to be beneficial for treated individuals. First, there must be treatment heterogeneity; second, in case of treatment heterogeneity, clinical predictors to identify people who would benefit from one treatment more than from others must be available. There is an established meta-regression approach to assess these two prerequisites that relies on measuring the variability of a clinical outcome after treatment in placebo-controlled randomised trials. We recently applied this approach to the treatment of type 2 diabetes for the clinical outcomes of glycaemic control and body weight and repeat it for the clinical outcome of all-cause mortality.
Methods We performed a meta-regression analysis using digitalized individual participant information on time to death from 10 large cardiovascular outcome trials (7563 deaths from 99,746 participants) on DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors with respect to the variability of all-cause mortality and its potential predictors after treatment.
Results The adjusted difference in log(SD) values of time to death between the verum and placebo arms was −0.036 (95%- CI: −0.059; −0.013), showing larger variability of time to death in the placebo arms. No clinical predictors were found to explain treatment heterogeneity.
Conclusions This analysis suggests that the potential of the precision treatment approach in type 2 diabetes is low, at least with regard to improvement of all-cause mortality in population with high cardiovascular risk. This extends our previous findings for the clinical outcomes of glycaemic control and body weight.
Keywords Dipeptidyl peptidase-4 inhibitors · Glucagon-like peptide 1 · HbA1c · Meta-regression · Precision medicine · Sodium–glucose transporter 2 inhibitors · Type 2 diabetes mellitus
Annunziata Lapolla1 · Maria Grazia Dalfrà1 · Giuseppe Marelli2 · Mario Parrillo3 · Laura Sciacca4 · Maria Angela Sculli5 · Elena Succurro6 · Elisabetta Torlone7 · Ester Vitacolonna8
Received: 18 September 2024 / Accepted: 27 December 2024 / Published online: 22 January 2025 © Springer-Verlag Italia S.r.l., part of Springer Nature 2025
Proper nutrition is essential during pregnancy to ensure an adequate supply of nutrients to the foetus and adequate maternal weight gain. In pregnancy complicated by diabetes (both gestational and pre-gestational), diet in terms of both the intake and quality of carbohydrates is an essential factor in glycaemic control. Maternal BMI at conception defines the correct weight increase during gestation in order to reduce maternal-foetal complications related to hypo- or hyper-nutrition. The recommendations presented here, which are based on national and international guidelines and the most recently published data on nutrition in physiological pregnancy and pregnancy complicated by hyperglycaemia and/or obesity, are designed to help healthcare professionals prescribe suitable eating patterns to safeguard the health of the mother and the foetus.
原创:伤口治疗及造口护理中心
对于下肢溃疡这个疾病,我们已经在之前介绍过一些了,那么想要更深入的了解及治疗这个疾病,就需要完善的检查还有评估,今天我们来介绍一下,关伊下肢溃疡都需要哪些专业的检查和评估呢?
下肢静脉性溃疡,俗称“老烂腿”,是下肢静脉疾病的常见临床表现。下肢静脉性溃疡常常反复发作,溃疡久治不愈,严重影响患者的正常生活,因此一旦出现下肢静脉性溃疡的现象,患者应该及时到正规医院的血管外科就医,以查清病因,对症下药.
下肢静脉性溃疡,俗称“老烂腿”,是下肢静脉疾病的常见临床表现。下肢静脉性溃疡常常反复发作,溃疡久治不愈,严重影响患者的正常生活,因此一旦出现下肢静脉性溃疡的现象,患者应该及时到正规医院的血管外科就医,以查清病因,对症下药。
今天我们来了解一下下肢静脉的基本机构及特点。
糖尿病足是糖尿病后期最严重的并发症之一,据文献统计,糖尿病足的发病率在糖尿病住院病人中约占15%的比例,糖尿病鞋是针对糖尿病足的保护专门研发设计的新型健康鞋,其合适的选材与科学的做工,可有效保护糖尿病足的患者。
伤口世界平台生态圈,以“关爱人间所有伤口患者”为愿景,连接、整合和拓展线上和线下的管理慢性伤口的资源,倡导远程、就近和居家管理慢性伤口,解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考,最终以医院当日公布为准。
网友、医生言论仅代表其个人观点,不代表本站同意其说法,请谨慎参阅,本站不承担由此引起的法律责任。